Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

203 results
Display

Daratumumab in dialysis-dependent multiple myeloma

Jeyaraman , Bhasin A, Dayal N, Pathak S, Naithani R

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Necrobiotic Xanthogranuloma Coexists with Diffuse Normolipidemic Plane Xanthoma and Multiple Myeloma

Kim JG, Kim HR, You MH, Shin DH, Choi JS, Bae YK

Necrobiotic xanthogranuloma (NXG), is a rare multisystem disease that manifests as cutaneous inflammatory lesions, and is commonly associated with lymphoproliferative disease. Diffuse normolipemic plane xanthoma (NX), is also a rare,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment

Lee SR, Choi H, Lee BH, Kang KW, Yu ES, Kim DS, Park Y, Choi CW, Kim BS, Sung HJ

BACKGROUND/AIMS: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Optimizing carfilzomib use in multiple myeloma treatment

Yoon SS

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cellular immunotherapy in multiple myeloma

Vo MC, Lakshmi TJ, Jung SH, Cho D, Park HS, Chu TH, Lee HJ, Kim HJ, Kim SK, Lee JJ

In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma

Lee HY, Park CJ, Ahn A, Lee MY, Cho YU, Jang S, Seo EJ, Lee KH, Lee JH

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cutaneous Angiosarcoma of the Foot Accompanied by Multiple Myeloma: The First Case Report

Jo JW, Shin YB, Kwon CI, Kim CY

  • KMID: 2457693
  • Korean J Dermatol.
  • 2019 Aug;57(7):399-402.
Although the exact etiology of cutaneous angiosarcoma remains unclear, MYC gene amplification has been recently discovered as a new pathogenesis. MYC is a proto-oncogene, and aberration of MYC signaling in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Simultaneous presentation of plasma cell myeloma and hairy cell leukemia

Carulli G, Sammuri P, Ottaviano

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diffuse Normolipemic Plane Xanthomatosis with Immunoglobulin-Lambda Light-Chain Deposition in a Patient with Multiple Myeloma

Lee SH, Shin JY, Lee SH, Park YL

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Diffuse Normolipemic Plane Xanthoma Associated with Multiple Myeloma

Kim WO, Ryoo YW, Kim SA

  • KMID: 2446920
  • Korean J Dermatol.
  • 2019 Mar;57(3):140-144.
Diffuse plane xanthoma (DPX) presents with symmetric yellow-orange plaques primarily on the neck, upper trunk, flexural folds, and the periorbital region. Based on serum lipid and lipoprotein levels, these xanthomas...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma

Lee SS, Lee JJ

This study investigated the efficacy and safety of melphalan, cyclophosphamide, and dexamethasone (MCD) as a salvage regimen for heavily treated relapsed or refractory multiple myeloma patients. We retrospectively analyzed a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
First Case of Plasma Cell Myeloma With Brown Tumor Features Unrelated to Hyperparathyroidism

Kim H, Kim K, Cho SR, Kim HJ, Kim SH

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
HBsAg-Negative, Anti-HBc–Negative Patients Still Have a Risk of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma

Park H, Kim DY, Kim SJ, Chung H, Cho H, Jang JE, Cheong JW, Min YH, Song JW, Kim JS

PURPOSE: Although hepatitis B surface antigen (HBsAg)–negative, hepatitis B core antibody (anti-HBc)–negative patients are not considered to be at risk for hepatitis B virus (HBV)–related hepatitis, the actual risk remains...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Emergence of chronic myeloid leukemia following autologous stem cell transplantation in a young woman with multiple myeloma

Barrett A, Glavey S, Sargent J, Thornton P, Murphy P, Quinn J

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Multiple myeloma in Korea: risk stratification and initial treatment

Yoon SS

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Central Nervous System Involvement in a Patient with Multiple Myeloma Manifesting as an Intraventricular Mass with Leptomeningeal Spread

Lee JE, Lee EJ, Huh HJ, Chung JW, Lee EK, Lee HJ

Central nervous system involvement in multiple myeloma (CNS-MM) is a rare condition. Various manifestations of CNS-MM have been reported, including dural, parenchymal, and leptomeningeal involvement. Among them, leptomeningeal involvement is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents

Lee SE, Jeon YW, Yoon JH, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG, Kim DW, Lee JW, Min WS, Min CK

BACKGROUND: The aim of this study was to evaluate the effects of darbepoetin alfa (DA) on hemoglobin (Hb) concentration and the need for transfusions in multiple myeloma (MM) patients receiving...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma

Byun JM, Lee J, Shin SJ, Kang M, Yoon SS, Koh Y

BACKGROUND: High-dose melphalan (HDMEL) represents the standard conditioning regimen before autologous stem cell transplant (ASCT) in multiple myeloma (MM), but recent updates have suggested combination of melphalan with bulsulfan (BUMEL)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Nonsecretory Multiple Myeloma Presenting as Recurrent Vertebral Compression Fractures in an Older Male Patient

Maeng YH, Hyun CL, Han SH, Seong GM, Song DH, An HJ, Koh HM

Nonsecretory multiple myeloma is a rare variant of multiple myeloma characterized by the proliferation of clonal plasma cells in the bone marrow. It is difficult to establish an early and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical significance of trabecular bone score for prediction of pathologic fracture risk in patients with multiple myeloma

Lee EM, Kim B

OBJECTIVES: Osteolytic bone lesions are common complications in multiple myeloma (MM), and can have an impact on quality of life due to the risk of fractures. Trabecular bone score (TBS)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr